|
Name |
Koaburaside
|
| Molecular Formula | C14H20O9 | |
| IUPAC Name* |
(2S,3R,4S,5S,6R)-2-(4-hydroxy-3,5-dimethoxyphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
|
|
| SMILES |
COC1=CC(=CC(=C1O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
|
|
| InChI |
InChI=1S/C14H20O9/c1-20-7-3-6(4-8(21-2)10(7)16)22-14-13(19)12(18)11(17)9(5-15)23-14/h3-4,9,11-19H,5H2,1-2H3/t9-,11-,12+,13-,14-/m1/s1
|
|
| InChIKey |
SWHCKWOYUSDWOF-RGCYKPLRSA-N
|
|
| Synonyms |
Koaburaside; 41653-73-0; (2S,3R,4S,5S,6R)-2-(4-hydroxy-3,5-dimethoxyphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol; J8R952KQV3; beta-D-Glucopyranoside, 4-hydroxy-3,5-dimethoxyphenyl; (2S,3R,4S,5S,6R)-2-(4-Hydroxy-3,5-dimethoxyphenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; UNII-J8R952KQV3; 4-Hydroxy-3,5-dimethoxyphenyl Beta-D-glucopyranoside; CHEMBL513117; DTXSID301045650; ZINC33832141; AKOS032962323; Q15426244; (-)-3,5-Dimethoxy-4-hydroxyphenyl beta-D-glucopyranoside; 3,5-dimethoxy-4-hydroxyphenol-1-O-beta-d-glucopyranoside; 4-HYDROXY-3,5-DIMETHOXYPHENYL .BETA.-D-GLUCOPYRANOSIDE; (-)-3,5-DIMETHOXY-4-HYDROXYPHENYL .BETA.-D-GLUCOPYRANOSIDE
|
|
| CAS | 41653-73-0 | |
| PubChem CID | 5318820 | |
| ChEMBL ID | CHEMBL513117 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 332.3 | ALogp: | -0.9 |
| HBD: | 5 | HBA: | 9 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 138.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 23 | QED Weighted: | 0.465 |
| Caco-2 Permeability: | -6.106 | MDCK Permeability: | 0.00005780 |
| Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.274 |
| Human Intestinal Absorption (HIA): | 0.719 | 20% Bioavailability (F20%): | 0.005 |
| 30% Bioavailability (F30%): | 0.809 |
| Blood-Brain-Barrier Penetration (BBB): | 0.449 | Plasma Protein Binding (PPB): | 44.27% |
| Volume Distribution (VD): | 0.505 | Fu: | 27.40% |
| CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.589 |
| CYP2C19-inhibitor: | 0.012 | CYP2C19-substrate: | 0.808 |
| CYP2C9-inhibitor: | 0.001 | CYP2C9-substrate: | 0.308 |
| CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.365 |
| CYP3A4-inhibitor: | 0.004 | CYP3A4-substrate: | 0.033 |
| Clearance (CL): | 4.384 | Half-life (T1/2): | 0.898 |
| hERG Blockers: | 0.171 | Human Hepatotoxicity (H-HT): | 0.179 |
| Drug-inuced Liver Injury (DILI): | 0.043 | AMES Toxicity: | 0.172 |
| Rat Oral Acute Toxicity: | 0.008 | Maximum Recommended Daily Dose: | 0.008 |
| Skin Sensitization: | 0.7 | Carcinogencity: | 0.1 |
| Eye Corrosion: | 0.011 | Eye Irritation: | 0.118 |
| Respiratory Toxicity: | 0.045 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004076 | ![]() |
0.671 | D06BQU | ![]() |
0.463 | ||
| ENC002201 | ![]() |
0.505 | D0H3KI | ![]() |
0.388 | ||
| ENC004909 | ![]() |
0.488 | D0TC7C | ![]() |
0.370 | ||
| ENC004798 | ![]() |
0.488 | D0I9HF | ![]() |
0.364 | ||
| ENC005772 | ![]() |
0.475 | D01TNW | ![]() |
0.333 | ||
| ENC004797 | ![]() |
0.471 | D0H2RI | ![]() |
0.329 | ||
| ENC003813 | ![]() |
0.469 | D07NSU | ![]() |
0.329 | ||
| ENC003752 | ![]() |
0.464 | D0T5BC | ![]() |
0.319 | ||
| ENC004073 | ![]() |
0.460 | D0B8UJ | ![]() |
0.319 | ||
| ENC005169 | ![]() |
0.452 | D05ZYM | ![]() |
0.312 | ||